G1T 38

Drug Profile

G1T 38

Alternative Names: G1T 38

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator G1 Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Cancer

Most Recent Events

  • 04 Apr 2017 G1 Therapeutics completes a phase I trial in Cancer (In volunteers) in the Netherlands (PO) (NCT02821624)
  • 01 Apr 2017 Pharmacodynamics data from two preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 10 Jan 2017 Interim adverse events data from a phase I trial in cancer released by G1 Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top